AR047749A1 - CRYSTAL COMPOSITION CONTAINING ESCITALOPRAM - Google Patents
CRYSTAL COMPOSITION CONTAINING ESCITALOPRAMInfo
- Publication number
- AR047749A1 AR047749A1 ARP050100683A ARP050100683A AR047749A1 AR 047749 A1 AR047749 A1 AR 047749A1 AR P050100683 A ARP050100683 A AR P050100683A AR P050100683 A ARP050100683 A AR P050100683A AR 047749 A1 AR047749 A1 AR 047749A1
- Authority
- AR
- Argentina
- Prior art keywords
- escitalopram
- particles
- composition containing
- crystal composition
- escitalopram oxalate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Partículas cristalinas de oxalato de escitalopram que tienen o bien una amplia distribucion de tamano de partícula o comprenden por lo menos 0,01 % (p/p) de Z-4-(4-dimetilamino-1-(4-fluorfenil)-but-1-enilo)-3-hidroxi-metil-benzonitrilo, donde dichas partículas son apropiadas para ser usadas en compresion directa. Forma de dosificacion farmacéutica unitaria que contiene dichas partículas cristalinas de oxalato de escitalopram así como también métodos de manufactura de dichas partículas de oxalato de escitalopram. Método para la reduccion de la cantidad de hidroxilo que contiene impurezas en una solucion de citalopram o escitalopram. Método de manufactura de partículas.Crystalline particles of escitalopram oxalate that have either a wide particle size distribution or comprise at least 0.01% (w / w) of Z-4- (4-dimethylamino-1- (4-fluorphenyl) -but -1-enyl) -3-hydroxy-methyl-benzonitrile, where said particles are suitable for use in direct compression. Unitary pharmaceutical dosage form containing said crystalline particles of escitalopram oxalate as well as manufacturing methods of said escitalopram oxalate particles. Method for reducing the amount of hydroxyl containing impurities in a solution of citalopram or escitalopram. Particle manufacturing method.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200400382 | 2004-03-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR047749A1 true AR047749A1 (en) | 2006-02-15 |
Family
ID=36607154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050100683A AR047749A1 (en) | 2004-03-05 | 2005-02-24 | CRYSTAL COMPOSITION CONTAINING ESCITALOPRAM |
Country Status (9)
| Country | Link |
|---|---|
| KR (1) | KR20060126587A (en) |
| CN (3) | CN101492436A (en) |
| AR (1) | AR047749A1 (en) |
| IL (1) | IL177504A0 (en) |
| MY (1) | MY142756A (en) |
| PE (1) | PE20051162A1 (en) |
| SG (1) | SG159504A1 (en) |
| TW (1) | TW200605916A (en) |
| ZA (1) | ZA200607382B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114763343A (en) * | 2021-01-14 | 2022-07-19 | 浙江华海药业股份有限公司 | Method for purifying citalopram or S-citalopram |
| CN113663356B (en) * | 2021-08-23 | 2022-09-23 | 广西埃索凯新材料科技有限公司 | Crystallization impurity removal monitoring system applied to manganese sulfate production |
-
2005
- 2005-02-17 TW TW094104639A patent/TW200605916A/en unknown
- 2005-02-21 KR KR1020067017907A patent/KR20060126587A/en not_active Application Discontinuation
- 2005-02-21 CN CNA2009100028561A patent/CN101492436A/en active Pending
- 2005-02-21 ZA ZA200607382A patent/ZA200607382B/en unknown
- 2005-02-21 CN CNA2005800069400A patent/CN1925844A/en active Pending
- 2005-02-21 SG SG201000567-6A patent/SG159504A1/en unknown
- 2005-02-21 CN CNA2009100028557A patent/CN101492435A/en active Pending
- 2005-02-24 AR ARP050100683A patent/AR047749A1/en not_active Application Discontinuation
- 2005-03-02 PE PE2005000241A patent/PE20051162A1/en not_active Application Discontinuation
- 2005-03-03 MY MYPI20050870A patent/MY142756A/en unknown
-
2006
- 2006-08-15 IL IL177504A patent/IL177504A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG159504A1 (en) | 2010-03-30 |
| CN1925844A (en) | 2007-03-07 |
| IL177504A0 (en) | 2006-12-10 |
| CN101492436A (en) | 2009-07-29 |
| CN101492435A (en) | 2009-07-29 |
| ZA200607382B (en) | 2008-05-28 |
| TW200605916A (en) | 2006-02-16 |
| KR20060126587A (en) | 2006-12-07 |
| PE20051162A1 (en) | 2006-01-16 |
| MY142756A (en) | 2010-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0508769A (en) | tamper-resistant dosage form comprising an adsorbent and an adverse agent | |
| ATE530577T1 (en) | EPHA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF APPLICATION THEREOF | |
| EP2520311A3 (en) | Method of treating hemolytic disease | |
| ATE314062T1 (en) | COMPOSITIONS FOR DELIVERING CORTISOL ANTAGONISTS | |
| MA33044B1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING GLUCOPYRANOSYL DIPHENYLMETHANE DERIVATIVES, ITS GALENIC DOSAGE FORM, PREPARATION METHOD AND USES FOR ENHANCED GLYCEMIC REGULATION IN PATIENT | |
| ES2523660T3 (en) | Composition for an electrode material, use of it and procedure to produce a solar cell | |
| JP2005507881A5 (en) | ||
| WO2008069889A3 (en) | Methods of treating hemolytic anemia | |
| WO2007143607A3 (en) | Method of treating atrophic vaginitis | |
| CL2007002018A1 (en) | COMPOUNDS DERIVED FROM SUBSTITUTED ISOXAZOLINS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND USE OF THE COMPOUND FOR THE TREATMENT OF A DISEASE CAUSED BY AN INCREASE IN THE CELL PROLIFERATION. | |
| AR109263A2 (en) | COMPOSITION INCLUDING MOXIDECTINE | |
| CY1111369T1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING 3- (3-DIMETHYLAMINE-1-ETHYL-2-Methyl-PROPYL) -PHENOL AND PARAKETAMOL | |
| MX2010002926A (en) | Thieno-and furo-pyrimidine modulators of the histamine h4 receptor. | |
| WO2005023193A3 (en) | Methods of treating endometriosis | |
| WO2005013947A3 (en) | Means and methods for treating a disease which is associated with an excess transport of hyaluronan across a lipid bilayer | |
| SE0200895D0 (en) | New pharmaceutical composition | |
| BR0307518A (en) | Pharmaceutical Composition | |
| EA201070806A1 (en) | COMPOSITION OF SLOW-FINGING ON THE BASIS OF THE ASSOCIATION OF GLYCOGEN AND ALGINATE | |
| AR047749A1 (en) | CRYSTAL COMPOSITION CONTAINING ESCITALOPRAM | |
| WO2006048261A3 (en) | Oral solid dosage forms containing a low dose of estradiol | |
| EA200601641A1 (en) | CRYSTAL COMPOSITION CONTAINING ESCYTAL PREMAX OXALATE | |
| BRPI0415571A (en) | cleaning compositions | |
| UY28789A1 (en) | CRYSTAL COMPOSITION CONTAINING SCITALOPRAM | |
| SE0000303D0 (en) | Novel compounds | |
| DE50207110D1 (en) | COMBINATION PREPARATION FOR THE TREATMENT OF DIABETES MELLITUS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |